요실금 치료제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 약물 종류별, 성별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)

Urinary Incontinence Therapeutics Market Summary

The global urinary incontinence therapeutics market size was estimated at USD 4.32 billion in 2024 and is projected to reach USD 6.95 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. This growth is primarily driven by the increasing prevalence of urinary incontinence among aging populations and the growing demand for effective therapeutic interventions that address bladder dysfunction.

According to a May 2023 report by Dovepress, the prevalence of female urinary incontinence was found to be 24.8%, with stress incontinence accounting for 12.7%, mixed incontinence for 8.0%, and urgency incontinence for 4.1%. The study indicated that prevalence increased progressively with age and body mass index, emphasizing the need for early diagnosis and effective therapy. Rising awareness among patients and healthcare providers has improved diagnosis and management rates, supporting higher treatment adoption. Advancements in B3-adrenoceptor agonists and antimuscarinic agents are improving outcomes across patient groups, while wider access to oral and non-invasive options is enhancing adherence. Expanding retail and online pharmacy networks are ensuring consistent medication availability, reinforcing market performance across regions.

The market is expanding as pharmaceutical companies focus on developing targeted and safer therapies addressing persistent unmet needs. For instance, in April 2024, Lupin Ltd introduced Mirabegron, a generic alternative to Myrbetriq, aimed at managing overactive bladder in the U.S. The introduction of such generics and novel mechanisms of action is diversifying treatment options and improving accessibility. Investments in research programs to enhance efficacy and minimize side effects are creating opportunities for the development of differentiated therapies. The presence of branded and generic drugs ensures cost flexibility, improving treatment compliance. Strategic collaborations between leading players and research organizations are accelerating development timelines and expanding the therapeutic pipeline. Continuous lifecycle management and post-approval studies are reinforcing product positioning, sustaining long-term competitiveness, and revenue stability.

Market expansion is further supported by rising healthcare expenditures and increasing access to urology and women's health services across both developed and emerging regions. For instance, in October 2025, global data showed that the number of people aged 60 and older is projected to double from 1 billion in 2020 to 2.1 billion by 2050. As this population segment grows, the burden of urinary incontinence and related geriatric conditions is expected to rise, driving demand for effective and accessible treatment options. Healthcare providers are prioritizing the quality of life of older adults through improved disease management, which is stimulating innovation in therapeutic strategies. Advancements in drug delivery technologies are improving treatment precision and convenience, while expanded clinical research in overactive bladder and mixed incontinence is driving the evolution of combination regimens. Sustained innovation, efficient distribution systems, and growing clinical adoption are expected to maintain a stable growth trajectory for the urinary incontinence therapeutics market through the forecast period.

Global Urinary Incontinence Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global urinary incontinence therapeutics market report based on type, drug class, gender, distribution channel, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Stress Incontinence
• Urge Incontinence
• Overflow Incontinence
• Functional Incontinence
• Other Types
• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Anticholinergics
• Beta-3 Adrenoceptor Agonists
• Alpha Blockers
• Estrogen
• Desmopressin
• Tricyclic Antidepressants
• Other Drug Classes
• Gender Outlook (Revenue, USD Million, 2021 - 2033)
• Male
• Female
• Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Drug Class
  • 1.2.3. Gender
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Urinary Incontinence Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Urinary Incontinence Therapeutics Market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Stress Incontinence
  • 4.4.1. Stress Incontinence Market, 2021 - 2033 (USD Million)
• 4.5. Urge Incontinence
  • 4.5.1. Urge Incontinence Market, 2021 - 2033 (USD Million)
• 4.6. Overflow Incontinence
  • 4.6.1. Overflow Incontinence Market, 2021 - 2033 (USD Million)
• 4.7. Functional Incontinence
  • 4.7.1. Functional Incontinence Market, 2021 - 2033 (USD Million)
• 4.8. Other Types
  • 4.8.1. Other Types Market, 2021 - 2033 (USD Million)

Chapter 5. Urinary Incontinence Therapeutics Market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2024 & 2033
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
• 5.4. Anticholinergics
  • 5.4.1. Anticholinergics Market, 2021 - 2033 (USD Million)
• 5.5. Beta-3 Adrenoceptor Agonists
  • 5.5.1. Beta-3 Adrenoceptor Agonists Market, 2021 - 2033 (USD Million)
• 5.6. Alpha Blockers
  • 5.6.1. Alpha Blockers Market, 2021 - 2033 (USD Million)
• 5.7. Estrogen
  • 5.7.1. Estrogen Market, 2021 - 2033 (USD Million)
• 5.8. Desmopressin
  • 5.8.1. Desmopressin Market, 2021 - 2033 (USD Million)
• 5.9. Tricyclic Antidepressants
  • 5.9.1. Tricyclic Antidepressants Market, 2021 - 2033 (USD Million)
• 5.10. Other Drug Classes
  • 5.10.1. Other Drug Classes Market, 2021 - 2033 (USD Million)

Chapter 6. Urinary Incontinence Therapeutics Market: Gender Business Analysis

• 6.1. Gender Market Share, 2024 & 2033
• 6.2. Gender Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by gender, 2021 to 2033 (USD Million)
• 6.4. Male
  • 6.4.1. Male Market, 2021 - 2033 (USD Million)
• 6.5. Female
  • 6.5.1. Female Market, 2021 - 2033 (USD Million)

Chapter 7. Urinary Incontinence Therapeutics Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2033
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 8. Urinary Incontinence Therapeutics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Urinary Incontinence Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Gender Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Gender Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. U.S. Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Gender Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Gender Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. UK Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Gender Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Gender Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Gender Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Gender Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Gender Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Gender Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Gender Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Gender Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Gender Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Gender Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Gender Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Gender Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Gender Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Gender Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Gender Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Gender Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Gender Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Gender Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Gender Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Pfizer Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. AbbVie Inc.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Astellas Pharma Inc.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Johnson & Johnson
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Viatris Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Teva Pharmaceutical Industries Ltd.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Sanofi S.A.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. GlaxoSmithKline plc
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Bayer AG
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. Ferring Pharmaceuticals
    • 9.5.11.1. Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic Initiatives